Bristol Myers Squibb has reported topline results from the Phase I/II TRANSCEND CLL 004 trial of Breyanzi (lisocabtagene maraleucel) in relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) adults.

The open-label, single-arm, multicentre trial has been designed for assessing the CD19-directed CAR T cell therapy in these patients.

The trial’s Phase I dose escalation section evaluated Breyanzi’s safety and recommended dose for the subsequent Phase II expansion cohort.

Bristol Myers Squibb noted that the Phase II portion is evaluating Breyanzi at the recommended dose from the Phase I monotherapy arm.

Complete response rate, including complete remission with incomplete bone marrow recovery, was the primary endpoint of the trial’s Phase II part.

Data from the TRANSCEND CLL 004 trial showed that the study met the primary endpoint of complete response rate, compared to historical control in the prespecified patient subset with R/R CLL.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In this trial, no new safety signals were reported for Breyanzi.

Bristol Myers Squibb Cell Therapy Development senior vice-president, head Anne Kerber said: “CLL is an incurable disease with complex biology and immune dysregulation that has made the development of T cell-based therapies that provide deep remission very challenging.

“In a population that has limited options, the TRANSCEND CLL 004 study represents the first multicenter trial evaluating a CAR T cell therapy in heavily pre-treated patients with relapsed or refractory CLL or SLL, with results showing the potential of Breyanzi as a personalised one-time treatment approach for patients with this difficult-to-treat disease.”

Bristol Myers Squibb plans to complete a full evaluation of the results obtained from the TRANSCEND CLL 004 clinical trial.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.